$1,318.00
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Acute treatment of ischemic stroke
11 Long-term treatments
11 Palliative care
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Asundexian for Ischemic Stroke (August 29, 2022)
26 Milvexian for Ischemic Stroke (August 28 2022)
28 LT3001 for Ischemic Stroke (August 3, 2021)
29 TMS-007 for Ischemic Stroke (May 12, 2021)
32 KEY UPCOMING EVENTS
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 Simcere In-Licenses Avilex Pharma CNS Drug Candidate
35 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
39 Recent events
42 BIBLIOGRAPHY
43 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in prevalent cases of ischemic stroke, 2021–30
19 Figure 2: Overview of pipeline drugs for ischemic stroke in the US
19 Figure 3: Pipeline drugs for ischemic stroke, by company
20 Figure 4: Pipeline drugs for ischemic stroke, by drug type
20 Figure 5: Pipeline drugs for ischemic stroke, by classification
26 Figure 6: Asundexian for Ischemic Stroke (August 29, 2022): Phase II – PACIFIC-STROKE
29 Figure 7: LT3001 for Ischemic Stroke (August 3, 2021): Phase IIa – 201
31 Figure 8: TMS-007 for Ischemic Stroke (May 12, 2021): Phase IIa – Single IV Administration (JP)
32 Figure 9: Key upcoming events in ischemic stroke
33 Figure 10: Probability of success in the ischemic stroke pipeline
36 Figure 11: Clinical trials in stroke
36 Figure 12: Top 10 drugs for clinical trials in stroke
37 Figure 13: Top 10 companies for clinical trials in stroke
37 Figure 14: Trial locations in stroke
38 Figure 15: Stroke trials status
39 Figure 16: Stroke trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of ischemic stroke, 2021–30
17 Table 2: Marketed drugs for ischemic stroke
21 Table 3: Pipeline drugs for ischemic stroke in the US
25 Table 4: Asundexian for Ischemic Stroke (August 29, 2022)
27 Table 5: Milvexian for Ischemic Stroke (August 28 2022)
28 Table 6: LT3001 for Ischemic Stroke (August 3, 2021)
30 Table 7: TMS-007 for Ischemic Stroke (May 12, 2021)
35 Table 8: Historical global sales, by drug ($m), 2017–21
35 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!